Wells Fargo & Co set a $245.00 target price on Allergan (NYSE:AGN) in a research note published on Friday, January 5th. The brokerage currently has a buy rating on the stock.
A number of other equities research analysts have also commented on the stock. Argus lowered shares of Allergan from a buy rating to a hold rating and reduced their price objective for the company from $256.80 to $160.07 in a research note on Thursday, December 7th. JPMorgan Chase & Co. set a $275.00 price objective on shares of Allergan and gave the company a buy rating in a research note on Sunday, October 22nd. Morgan Stanley lowered shares of Allergan from an overweight rating to an equal weight rating and reduced their price objective for the company from $284.00 to $228.00 in a research note on Wednesday, September 20th. Zacks Investment Research lowered shares of Allergan from a hold rating to a sell rating in a research note on Tuesday, October 17th. Finally, Vetr lowered shares of Allergan from a strong-buy rating to a buy rating and set a $187.73 target price on the stock. in a research note on Wednesday, December 6th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the stock. Allergan presently has an average rating of Hold and an average price target of $227.56.
Allergan (NYSE:AGN) traded down $4.12 during mid-day trading on Friday, reaching $180.26. 2,933,248 shares of the company were exchanged, compared to its average volume of 2,720,000. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 1.18. Allergan has a twelve month low of $160.07 and a twelve month high of $256.80. The firm has a market cap of $61,320.00, a PE ratio of -7.98, a price-to-earnings-growth ratio of 1.38 and a beta of 1.11.
Allergan (NYSE:AGN) last posted its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 EPS for the quarter, beating the Zacks’ consensus estimate of $4.06 by $0.09. Allergan had a negative net margin of 47.27% and a positive return on equity of 8.00%. The company had revenue of $4.03 billion for the quarter, compared to analyst estimates of $4.04 billion. During the same period in the prior year, the firm posted $3.32 EPS. The company’s quarterly revenue was up 11.4% on a year-over-year basis. analysts predict that Allergan will post 16.27 EPS for the current fiscal year.
In related news, insider William Meury sold 11,807 shares of the firm’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $173.89, for a total transaction of $2,053,119.23. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Chris W. Bodine bought 3,030 shares of the business’s stock in a transaction on Thursday, December 7th. The shares were acquired at an average price of $164.77 per share, with a total value of $499,253.10. The disclosure for this purchase can be found here. Insiders have purchased 17,630 shares of company stock valued at $2,890,057 in the last 90 days. 0.36% of the stock is currently owned by corporate insiders.
Several hedge funds have recently bought and sold shares of AGN. Hudock Capital Group LLC increased its stake in shares of Allergan by 0.4% in the second quarter. Hudock Capital Group LLC now owns 571 shares of the company’s stock worth $138,000 after buying an additional 2 shares during the period. Pacific Center for Financial Services boosted its holdings in shares of Allergan by 1.3% during the 2nd quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock valued at $132,000 after buying an additional 7 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its holdings in shares of Allergan by 0.5% during the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 2,420 shares of the company’s stock valued at $611,000 after buying an additional 13 shares in the last quarter. Quadrant Capital Group LLC boosted its holdings in shares of Allergan by 1.4% during the 2nd quarter. Quadrant Capital Group LLC now owns 1,201 shares of the company’s stock valued at $235,000 after buying an additional 16 shares in the last quarter. Finally, Buckingham Asset Management LLC boosted its holdings in shares of Allergan by 2.6% during the 2nd quarter. Buckingham Asset Management LLC now owns 964 shares of the company’s stock valued at $234,000 after buying an additional 24 shares in the last quarter. 81.21% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “Allergan (AGN) Given a $245.00 Price Target at Wells Fargo & Co” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/31/allergan-agn-pt-set-at-245-00-by-wells-fargo-co.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.